EGFR and non-small cell lung carcinoma: Specifically, in NSCLC, QKI-6 has been shown to inhibit EMT processes by modulating the EGFR/SRC/STAT3 signaling pathway, thereby upregulating the expression of AGR2.320 QKI is suppressed in a variety of tumors, and its expression levels are strongly correlated with the aggressiveness, metastatic potential, and clinical outcomes of these tumors.